What's Happening?
Pace Life Sciences, a division of the Science and Technology company Pace, has appointed Andy Fenny as its new President. Fenny, who brings over 20 years of experience in the CDMO and pharmaceutical sectors, will lead the division from its base in Research
Triangle Park, North Carolina. His role will involve overseeing all aspects of the division, fostering collaboration across its eight sites, and enhancing service delivery from early development through to commercialization. Pace Life Sciences, a portfolio company of Leonard Green & Partners and Aurora Capital Partners, aims to support pharmaceutical and biotech clients in navigating complex regulatory environments and accelerating development timelines.
Why It's Important?
The appointment of Andy Fenny is a strategic move by Pace Life Sciences to strengthen its leadership and expand its capabilities in the life sciences sector. Fenny's extensive experience in commercial strategy and business development is expected to enhance Pace's ability to support its clients through the complexities of drug development and regulatory compliance. This leadership change is crucial as the pharmaceutical and biotech industries face increasing pressure to innovate and bring products to market swiftly, amidst rising costs and regulatory challenges.
